» Articles » PMID: 29124981

Chitosan and Its Derivatives As Vehicles for Drug Delivery

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2017 Nov 11
PMID 29124981
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Chitosan and its derivatives as vehicles for drug delivery can achieve the purpose of sustained release and controlled release for drugs, improve the stability of drugs, and reduce adverse drug reactions. So, the bioavailability of drugs can be enhanced. Therefore, chitosan and its derivatives have become a hotspot in the field of drug delivery. Their characteristics as drug delivery vectors were introduced, the types and applications were summarized. The development direction of chitosan and its derivatives in this field was also forecasted.

Citing Articles

Nanoparticles for the treatment of spinal cord injury.

Yang Q, Lu D, Wu J, Liang F, Wang H, Yang J Neural Regen Res. 2024; 20(6):1665-1680.

PMID: 39104097 PMC: 11688544. DOI: 10.4103/NRR.NRR-D-23-01848.


Microfluidic Synthesis of Scalable Layer-by-Layer Multiple Antigen Nano-Delivery Platform for SARS-CoV-2 Vaccines.

Xu Y, Masuda K, Groso C, Hassan R, Zhou Z, Broderick K Vaccines (Basel). 2024; 12(3).

PMID: 38543973 PMC: 10975406. DOI: 10.3390/vaccines12030339.


Role of Polymer Concentration on the Release Rates of Proteins from Single- and Double-Network Hydrogels.

Browne D, Briggs F, Asuri P Int J Mol Sci. 2023; 24(23).

PMID: 38069293 PMC: 10707672. DOI: 10.3390/ijms242316970.


The important role of miR-1-3p in cancers.

Dai S, Li F, Xu S, Hu J, Gao L J Transl Med. 2023; 21(1):769.

PMID: 37907984 PMC: 10617136. DOI: 10.1186/s12967-023-04649-8.


Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy.

Dubey A, Mostafavi E Front Chem. 2023; 11:1259435.

PMID: 37841202 PMC: 10568484. DOI: 10.3389/fchem.2023.1259435.


References
1.
Bhattarai N, Gunn J, Zhang M . Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2009; 62(1):83-99. DOI: 10.1016/j.addr.2009.07.019. View

2.
Millotti G, Perera G, Vigl C, Pickl K, Sinner F, Bernkop-Schnurch A . The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery. Drug Deliv. 2010; 18(3):190-7. DOI: 10.3109/10717544.2010.522611. View

3.
Yang J, Chen J, Pan D, Wan Y, Wang Z . pH-sensitive interpenetrating network hydrogels based on chitosan derivatives and alginate for oral drug delivery. Carbohydr Polym. 2012; 92(1):719-25. DOI: 10.1016/j.carbpol.2012.09.036. View

4.
Termsarasab U, Yoon I, Park J, Moon H, Cho H, Kim D . Polyethylene glycol-modified arachidyl chitosan-based nanoparticles for prolonged blood circulation of doxorubicin. Int J Pharm. 2014; 464(1-2):127-34. DOI: 10.1016/j.ijpharm.2014.01.015. View

5.
Wang C, Mallela J, Garapati U, Ravi S, Chinnasamy V, Girard Y . A chitosan-modified graphene nanogel for noninvasive controlled drug release. Nanomedicine. 2013; 9(7):903-11. PMC: 3783966. DOI: 10.1016/j.nano.2013.01.003. View